The incidence of the most common recurrence sites of ESMO field direct attack IB-IIIA NSCLC is as low as 6%: ADAURA Blockbuster Update

The Annual Meeting of the European Society of Oncology (ESMO) is the most prestigious and influential oncology conference

On the morning of the 11th local time, the oral report was held, and the ADAURA study announced the updated results

1

background

The third generation of EGFR TKI osimtinib effectively and selectively inhibits EGFR-sensitive mutations and EGFR T790M-resistant mutations

method

Eligible patients (>18 years [Japan/Taiwan 20 years], WHO PS 0/1, complete resection of EGFR-sensitive mutations, IB-IIIA staging [AJCC 7th Edition] NSCLC, permissible adjuvant chemotherapy) were randomized and randomly assigned to receive osimiminib (80 mg once daily) or placebo (3 years)

1

background

outcome

Globally, 682 patients were randomized, with 339 and 343 in the oscitinib and placebo groups

conclusion

Results from additional 2 years of follow-up showed that adjuvant treatment with osimertinib conferred sustained DFS benefits

compared with placebo.

Overall, adjuvant therapy with osimtinib reduced the risk of disease progression in patients with stage II-IIIA by 77% compared with placebo (DFS HR=0.
23).

Benefit from DFS has been observed regardless of whether previous adjuvant chemotherapy has been received, and osimerinib has also significantly improved CNS DFS in patients with stage II-IIIA
.
This analysis is similar
to previous results.

More mature data further validate that adjuvant chemotherapy ± adjuvant chemotherapy is the standard of choice
for patients with complete resection and adjuvant chemotherapy in patients with EGFR-sensitive stage IB-IIIA NSCLC 。 References: LBA47-Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA.
2022 ESMO.
Editor: Koen Layout: Koen Executive: Yogi